Necroptosis-driving genes
adaptive immunity
liver neoplasms
lymphocytes
tumor-infiltrating
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
21
01
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
5
2022
Statut:
ppublish
Résumé
Hepatocellular carcinoma (HCC) is a highly lethal cancer and the second leading cause of cancer-related deaths worldwide. As demonstrated in other solid neoplasms and HCC, infiltrating CD8 We investigated the association between the main necroptosis-related genes, that is, Our findings highlighted the immunogenetic role of necroptosis and its potential prognostic role in HCC: RIPK1, RIPK3 and MLKL-p were found significantly associated with intratumoral CD3 Our results confirmed the immunogenetic properties of necroptosis (NCP) in human HCC, showing that tumor-infiltrating lymphocytes (TILs) and, specifically, CD8+ T cells accumulate in tumors with higher expression of the necroptosis-related genes. These results suggest the importance of further studies to better assess the specific composition, as well as the functional features of the immune environment associated with a necroptotic signature in order to explore new possible diagnostic and immunotherapeutic scenarios.
Sections du résumé
BACKGROUND
Hepatocellular carcinoma (HCC) is a highly lethal cancer and the second leading cause of cancer-related deaths worldwide. As demonstrated in other solid neoplasms and HCC, infiltrating CD8
METHODS
We investigated the association between the main necroptosis-related genes, that is,
RESULTS
Our findings highlighted the immunogenetic role of necroptosis and its potential prognostic role in HCC: RIPK1, RIPK3 and MLKL-p were found significantly associated with intratumoral CD3
CONCLUSIONS
Our results confirmed the immunogenetic properties of necroptosis (NCP) in human HCC, showing that tumor-infiltrating lymphocytes (TILs) and, specifically, CD8+ T cells accumulate in tumors with higher expression of the necroptosis-related genes. These results suggest the importance of further studies to better assess the specific composition, as well as the functional features of the immune environment associated with a necroptotic signature in order to explore new possible diagnostic and immunotherapeutic scenarios.
Identifiants
pubmed: 35264437
pii: jitc-2021-004031
doi: 10.1136/jitc-2021-004031
pmc: PMC8915343
pii:
doi:
Substances chimiques
MLKL protein, human
EC 2.7.-
Protein Kinases
EC 2.7.-
RIPK1 protein, human
EC 2.7.11.1
RIPK3 protein, human
EC 2.7.11.1
Receptor-Interacting Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Int J Mol Sci. 2020 Feb 29;21(5):
pubmed: 32121394
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32209603
J Immunother Cancer. 2017 May 16;5:44
pubmed: 28515944
J Hepatol. 2017 Jun;66(6):1118-1119
pubmed: 28215597
Gut. 2021 Dec;70(12):2359-2372
pubmed: 33361348
Pathol Res Pract. 2020 Jun;216(6):152966
pubmed: 32360247
Cancer. 2014 Sep 15;120(18):2824-38
pubmed: 24897995
Trends Immunol. 2018 Feb;39(2):123-134
pubmed: 29236673
Cell Mol Life Sci. 2015 Jan;72(2):273-83
pubmed: 25274062
Oncotarget. 2015 Nov 3;6(34):35602-15
pubmed: 26415232
Oncotarget. 2016 Aug 30;7(35):57391-57413
pubmed: 27429198
Immunity. 2013 Feb 21;38(2):209-23
pubmed: 23438821
J Clin Invest. 2017 Jun 30;127(7):2662-2677
pubmed: 28628031
Hepatology. 2020 Dec;72(6):1987-1999
pubmed: 32112577
Nat Commun. 2021 May 11;12(1):2666
pubmed: 33976222
Cancer Immunol Res. 2016 May;4(5):419-30
pubmed: 26968206
Cancer Immunol Res. 2018 Jan;6(1):2-9
pubmed: 29298781
Cell Res. 2019 May;29(5):347-364
pubmed: 30948788
Immunol Rev. 2017 Nov;280(1):126-148
pubmed: 29027218
Sci Immunol. 2019 Jun 21;4(36):
pubmed: 31227597
Oncoimmunology. 2017 Apr 17;6(4):e1299302
pubmed: 28507808
Nature. 2016 Aug 11;536(7615):215-8
pubmed: 27487218
Nat Commun. 2015 Dec 04;6:8971
pubmed: 26634437
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Medicine (Baltimore). 2019 Jan;98(2):e13923
pubmed: 30633166
Cell Rep. 2016 Apr 12;15(2):274-87
pubmed: 27050509
Nucleic Acids Res. 2012 Jan;40(Database issue):D109-14
pubmed: 22080510
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Oncotarget. 2018 Apr 03;9(25):17300-17308
pubmed: 29707109
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Sci Rep. 2021 Jun 3;11(1):11743
pubmed: 34083572
Cell Death Discov. 2016 Dec 05;2:16089
pubmed: 27924226
Mol Cell. 2014 Nov 20;56(4):469-80
pubmed: 25459879
J Immunother Cancer. 2016 Nov 15;4:71
pubmed: 27879973
Medicine (Baltimore). 2018 Dec;97(50):e13301
pubmed: 30557978
Cell Rep. 2018 Apr 3;23(1):181-193.e7
pubmed: 29617659
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):259-266
pubmed: 30716362
Semin Cancer Biol. 2017 Dec;47:185-195
pubmed: 28782608
Mol Cell Biol. 2011 Jul;31(14):2934-46
pubmed: 21576359
Mol Cancer. 2019 May 23;18(1):100
pubmed: 31122251
FEBS J. 2015 Jan;282(1):19-31
pubmed: 25327580